Piyush Goyal Champions Biopharma Startups to Propel India's Bioeconomy

On November 8, 2026, Union Minister of Commerce and Industry, Shri Piyush Goyal, chaired a pivotal roundtable at Vanijya Bhawan, New Delhi, aimed at enhancing India's [biopharma](/topic/healthcare-pharma) startup ecosystem and accelerating the growth of the bioeconomy. The event, organized by the Department for Promotion of Industry and Internal Trade (DPIIT) in collaboration with NITI Aayog and NITI Frontier Tech Hub, gathered key stakeholders, including policymakers, industry leaders, and biopharma startups, to discuss actionable strategies for positioning India as a global leader in the bioeconomy.

In his address, Goyal stressed the importance of leveraging India's scientific capabilities and entrepreneurial talent. "We must act decisively to harness our strengths in science and innovation, ensuring that India emerges as a frontrunner in the global bioeconomy landscape," he stated. His remarks underscored the urgency of implementing faster regulatory approvals, improving access to finance, and fostering stronger collaboration among industry, academia, and government.

The roundtable discussions revolved around several critical themes aimed at bolstering the biopharma startup ecosystem. Participants highlighted the necessity of streamlined regulations and proposed the establishment of a Regulatory Sandbox to facilitate innovation while ensuring safety and compliance. Goyal emphasized the need for a Single Window Clearance system to expedite approvals and align with global regulatory standards.

One of the significant initiatives discussed was the Biopharma SHAKTI program, announced in the [Union Budget](/topic/ministry-of-finance) for 2026-27, which aims to provide financial and infrastructural support to biopharma startups. The program is designed to foster innovation by reducing operational costs through shared resources such as laboratories, testing facilities, and clinical trial centers.

"By developing shared infrastructure, we can significantly lower the barriers to entry for startups, enabling them to scale their innovations more effectively," Goyal remarked. The emphasis on collaboration among startups, industry, and government was echoed by Ms. Debjani Ghosh, a Distinguished Fellow at NITI Aayog, who stated, "A cohesive approach is essential for building a competitive bioeconomy that can thrive on innovation and collaboration."

The roundtable also addressed the critical need to enhance research capabilities within the biopharma sector. Prof. Gobardhan Das, a member of NITI Aayog, highlighted the importance of translating scientific discoveries into commercially viable products. "We must strengthen our research infrastructure and ensure that our innovations reach the market swiftly and efficiently," he asserted.

Participants discussed the need for expedited customs clearance for laboratory equipment and reagents, which is vital for maintaining the momentum of research and development activities. The call for simplified access to government schemes and regulatory support was a recurring theme, with stakeholders advocating for stronger inter-ministerial coordination to facilitate coherent policy interventions.

Startups play a crucial role in driving innovation within the biopharma sector. The roundtable discussions highlighted the unique challenges faced by these entities, including limited access to funding and regulatory hurdles. Goyal urged participants to focus on creating an environment conducive to startup growth, emphasizing the need for time-bound action on the recommendations emerging from the discussions.

"We must ensure that our startups have the resources and support they need to thrive. This includes not only financial backing but also a regulatory framework that encourages innovation and reduces bureaucratic delays," Goyal stated.

As the roundtable concluded, Goyal reiterated the importance of immediate action on the recommendations discussed. The collective commitment from policymakers, industry leaders, and startups is essential for realizing the vision of a robust biopharma ecosystem in India. The emphasis on collaboration, regulatory reforms, and shared infrastructure is expected to pave the way for a vibrant bioeconomy that not only meets domestic needs but also positions India as a global leader in biopharmaceutical innovation.

The roundtable marks a significant step towards fostering a collaborative ecosystem that can drive innovation and growth in India's biopharma sector, ultimately contributing to the nation's economic development and global standing in the bioeconomy.